GlassScriptPhysician profile
Minaxi Rathod
NPI 1437137981
$1,694.23
in general payments reported to CMS, 2019-2025
13 companies · $342 in 2025
The $342 reported for 2025 was more than what a typical Infectious Disease provider received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $622 · 2020: $66.96 · 2021: $184 · 2022: $80.09 · 2023: $227 · 2024: $172 · 2025: $342.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $741.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $741.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $721.89 | 2019-2025 | Dovato, Cabenuva |
| Gilead Sciences, INC. | $398.82 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $172.20 | 2019-2025 | Pifeltro |
| Janssen Biotech, INC. | $107.39 | 2019-2022 | |
| Janssen Products, LP | $99.00 | 2021 | |
| Janssen Pharmaceuticals, INC | $44.98 | 2023 | Xarelto |
| Theratechnologies INC. | $34.29 | 2019 | |
| Astellas Pharma US INC | $33.85 | 2019 | |
| Smith+Nephew, INC. | $32.91 | 2019-2023 | Oasis, Grafix Pl |
| Tetraphase Pharmaceuticals, INC. | $18.02 | 2019 | |
| Shionogi INC | $15.84 | 2024 | Fetroja |
| Allergan, INC. | $15.04 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Minaxi Rathod listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.